The company, once called US Genomics, will use the funds to complete development of its first commercial systems for identifying pathogens in complex biological samples.
The firms have begun a validation sudy of the Down syndrome test, which runs on Illumina’s HiSeq platform.
Illumina will provide its DNA analysis technology, Barts will supply tissue samples, and Source BioScience will develop the test.
The company will investigate the use of PacBio's RS platform for use in the test protocol.
After verifying that organ transplant rejection corresponds to a rise in cell-free donor DNA in recipient blood samples, researchers from Stanford University developed a sequencing-based approach for assessing these donor DNA levels.
The startup will use its using next-generation sequencing-based technology for applications aimed at identifying biothreats.
The space is being housed at its headquarters and will run the company's planned Trisomy 21 test.
The molecular diagnostics firm currently has a patent application for a method of using DNA sequencing technology for identifying biomarkers of autoimmune disease.
Enzo plans to seek approval for and market MultiGen's antenatal infectious disease tests in New York and in other US regions.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.